Suppr超能文献

凉膈散,一种经典的中药方剂,通过胆碱能抗炎途径预防脂多糖诱导的炎症。

Liang-Ge-San, a classic traditional Chinese medicine formula, protects against lipopolysaccharide-induced inflammation through cholinergic anti-inflammatory pathway.

作者信息

Liu Jun-Shan, Wei Xi-Duan, Lu Zi-Bin, Xie Pei, Zhou Hong-Ling, Chen Yu-Yao, Ma Jia-Mei, Yu Lin-Zhong

机构信息

Department of Traditional Chinese Medicine, Southern Medical University, Guangzhou, P. R. China.

出版信息

Oncotarget. 2016 Apr 19;7(16):21222-34. doi: 10.18632/oncotarget.8452.

Abstract

Liang-Ge-San (LGS) is a classic formula in traditional Chinese medicine, which is widely used to treat acute lung injury (ALI), pharyngitis and amygdalitis in clinic. However, the underlying mechanisms remain poorly defined. In this study, we discovered that LGS exerted potent anti-inflammatory effects in lipopolysaccharide (LPS)-induced inflammation. We found that LGS significantly depressed the production of IL-6 and TNF-α in LPS-stimulated RAW 264.7 macrophage cells. The degradation and phosphorylation of IκBα and the nuclear translocation of NF-κB p65 were also inhibited. Moreover, LGS activated α7 nicotinic cholinergic receptor (α7nAchR). The blockage of α7nAchR by selective inhibitor methyllycaconitine (MLA) or α7nAchR siRNA attenuated the inhibitory effects of LGS on IκBα, NF-κB p65, IL-6 and TNF-α. Critically, LGS significantly inhibited inflammation in LPS-induced ALI rats through the activation of NF-κB signaling pathway. However, these protective effects could be counteracted by the treatment of MLA. Taken together, we first demonstrated anti-inflammatory effects of LGS both in vitro and in vivo through cholinergic anti-inflammatory pathway. The study provides a rationale for the clinical application of LGS as an anti-inflammatory agent and supports the critical role of cholinergic anti-inflammatory pathway in inflammation.

摘要

凉膈散(LGS)是中医经典方剂,临床广泛用于治疗急性肺损伤(ALI)、咽炎和扁桃体炎。然而,其潜在机制仍不清楚。在本研究中,我们发现凉膈散在脂多糖(LPS)诱导的炎症中发挥强大的抗炎作用。我们发现凉膈散显著抑制LPS刺激的RAW 264.7巨噬细胞中IL-6和TNF-α的产生。IκBα的降解和磷酸化以及NF-κB p65的核转位也受到抑制。此外,凉膈散激活α7烟碱型胆碱能受体(α7nAchR)。选择性抑制剂甲基lycaconitine(MLA)或α7nAchR siRNA阻断α7nAchR减弱了凉膈散对IκBα、NF-κB p65、IL-6和TNF-α的抑制作用。至关重要的是,凉膈散通过激活NF-κB信号通路显著抑制LPS诱导的ALI大鼠的炎症。然而,这些保护作用可被MLA治疗抵消。综上所述,我们首次证明凉膈散在体外和体内通过胆碱能抗炎途径发挥抗炎作用。该研究为凉膈散作为抗炎剂的临床应用提供了理论依据,并支持胆碱能抗炎途径在炎症中的关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/964c/5008280/9177c38b3fe3/oncotarget-07-21222-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验